Coronavirus (COVID-19) Vaccine Pipeline Assessment 2020

DUBLIN, May 11, 2020 /PRNewswire/ -- The "Coronavirus (COVID-19) Vaccine Pipeline Assessment 2020" report has been added to's offering.

This report provides a comprehensive analysis of the fast-evolving, high-growth global Coronavirus (COVID-19) vaccine market. The report offers the most up-to-date industry data on the actual market situation for the Coronavirus vaccine.

The report explores a detailed analysis of the introduction of the Coronavirus, pathogen characteristics, signs and symptoms, transmission, and prevention. It also evaluates the vaccines developed against MERS-CoV and SARS-CoV. The report reviews a clear insight into the funding of the Coronavirus vaccine research.

The report also offers comprehensive information about the recruiting clinical trials statement by phase, trial status, study sponsor name, and study phase. The report investigates detailed insights about countries, territories, or areas with reported laboratory-confirmed Coronavirus cases and deaths. Key trends in terms of collaboration and partnership deals are analyzed with details.

The report concludes with the profiles of the key vaccine developers in the global Coronavirus vaccine market. The key players are evaluated on the various parameters such as business overview, promising vaccine in clinical development, and recent development.

Report Scope

    --  Extensive coverage of the Coronavirus (COVID-19) vaccine under
    --  Detailed Insights of the Introduction, Pathogen Characteristics, Signs
        and Symptoms, Transmission and Prevention
    --  Provides Comprehensive Insights on the Funding of the Coronavirus
        Vaccine Research
    --  Thoroughly Evaluates Vaccines Developed Against MERS-CoV and SARS-CoV
    --  Reviews Most Recent Clinical Trials of the Coronavirus Vaccines
    --  Scrutinizes Countries, Territories or Areas with Reported
        Laboratory-Confirmed Coronavirus Cases and Deaths
    --  Provides Key Trends with Respect to Collaboration and Partnership Deals
    --  An Insightful Analysis of the Key Vaccine Developers Along with the
        Analysis of their Promising Vaccines in the Clinical Development, Phase,
        Platform Technology, and Recent Development

Key Topics Covered

1. Executive Summary

2. Coronavirus (COVID-19) - Introduction, Pathogen Characteristics, Signs and Symptoms, Transmission and Prevention
2.1 Introduction
2.2 Pathogen Characteristics
2.3 Signs and Symptoms
2.4 Transmission
2.5 Prevention

3. Funding in the Coronavirus (COVID-19) Vaccine Research

4. Vaccines Developed Against MERS-CoV

5. Vaccines Developed Against SARS-CoV

6. Coronavirus (COVID-19) Vaccine Clinical Trial Insights by Phase, Company and Country

7. Countries, Territories or Areas with Reported Laboratory-Confirmed Coronavirus (COVID-19) Cases and Deaths

8. Major Partnership and Collaboration Deals in the Coronavirus (COVID-19) Vaccine Market
8.1 Collaboration Deals
8.2 Partnership Deals

9. Key Vaccine Developers Analysis
9.1 University of Oxford
9.1.1 Business Overview
9.1.2 Promising Coronavirus Vaccines in the Clinical Development
9.1.3 Recent Development
9.2 Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline
9.3 Heat Biologics Inc./University of Miami
9.4 Inovio Pharmaceuticals Inc
9.5 Janssen Pharmaceutical
9.6 Sanofi Pasteur/GlaxoSmithKline (GSK)
9.7 Moderna/NIAID
9.8 Novavax
9.9 Sanofi Pasteur/Translate Bio Inc.
9.10 Vaxart Inc.
9.11 Altimmune
9.12 Medicago
9.13 BioNTech/Pfizer/Fosun Pharma
9.14 GeoVax/BravoVax
9.15 Arcturus Therapeutics/Duke-NUS
9.16 CanSino Biological Inc/Beijing Institute of Biotechnology
9.17 Takis Biotech/Applied DNA Sciences/Evvivax
9.18 Cobra Biologics/Karolinska Institute
9.19 Zydus Cadila
9.20 Codagenix/Serum Institute of India
9.21 Greffex
9.22 ExpreS2ion Biotechnologies ApS
9.23 Vaxil Bio Therapeutics
9.24 Flow Pharma Inc.
9.25 AJ Vaccines
9.26 Generex Biotechnology/EpiVax
9.27 Immunomic Therapeutics/EpiVax/PharmaJet
9.28 iBio Inc/CC-Pharming Ltd/Infectious Disease Research Institute
9.29 VIDO-InterVac/University of Saskatchewan/International Vaccine Institute
9.30 Tonix Pharmaceuticals/Southern Research
9.31 IAVI/Batavia Biosciences
9.32 Curevac
9.33 Imophoron Ltd/University of Bristol
9.34 BioNet Asia
9.35 Sinovac/Dynavax
9.37 University of Pittsburgh

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets